ETVAX – the first oral vaccine for protection against traveller’s diarrhoea caused by ETEC

Project Information

ETVAX

Grant agreement ID: 778253

DOI 10.3030/778253

Project closed

EC signature date 9 August 2017

Start date 1 June 2017

End date 31 May 2020

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 2 992 750,00

EU contribution € 2 992 750,00

Coordinated by

SCANDINAVIAN BIOPHARMA HOLDING AB
Sweden

Deliverables

Documents, reports (3)

Approval letter from Ethics Committee
Scientific paper on the results of the Phase IIb study
Approval letter from the Finnish Medicine Agency Fimea